Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Int. J. Mol. Sci. 2012, 13(7), 8482-8499; doi:10.3390/ijms13078482
Article

Chemopreventive Efficacy of Atorvastatin against Nitrosamine-Induced Rat Bladder Cancer: Antioxidant, Anti-Proliferative and Anti-Inflammatory Properties

1,2,†,* , 1,†,* , 1,†
, 1
, 3
, 3
, 4
, 2
, 2
 and 1,*
Received: 23 April 2012; in revised form: 14 June 2012 / Accepted: 2 July 2012 / Published: 9 July 2012
(This article belongs to the Special Issue Advances in Molecular Oncology)
View Full-Text   |   Download PDF [2305 KB, uploaded 19 June 2014]   |   Browse Figures
Abstract: To investigate the anti-carcinogenic effects of Atorvastatin (Atorva) on a rat bladder carcinogenesis model with N-butyl-N-(4-hydroxibutil)nitrosamine (BBN), four male Wistar rat groups were studied: (1) Control: vehicle; (2) Atorva: 3 mg/kg bw/day; (3) Carcinogen: BBN (0.05%); (4) Preventive Atorva: 3 mg/kg bw/day Atorva + BBN. A two phase protocol was used, in which the drug and the carcinogen were given between week 1 and 8 and tumor development or chemoprevention were expressed between week 9 and 20, when the bladders were collected for macroscopic, histological and immunohistochemical (p53, ki67, CD31) evaluation. Serum was assessed for markers of inflammation, proliferation and redox status. The incidence of bladder carcinoma was: control 0/8 (0%); Atorva 0/8 (0%); BBN 13/20 (65%) and Atorva + BBN 1/8 (12.5%). The number and volume of tumors were significantly lower in the Atorva + BBN group, with a marked reduction in hyperplasia, dysplasia and carcinoma in situ lesions. An anti-proliferative, anti-inflammatory and antioxidant profile was also observed in the preventive Atorva group. p53 and ki67 immunostaining were significantly increased in the BBN-treated rats, which was prevented in the Atorva + BBN group. No differences were found for CD31 expression. In conclusion, Atorvastatin had a clear inhibitory effect on bladder cancer development, probably due to its antioxidant, anti-proliferative and anti-inflammatory properties.
Keywords: bladder cancer; chemoprevention; atorvastatin; antioxidant; anti-proliferative; anti-inflammatory bladder cancer; chemoprevention; atorvastatin; antioxidant; anti-proliferative; anti-inflammatory
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Parada, B.; Reis, F.; Pinto, Â.; Sereno, J.; Xavier-Cunha, M.; Neto, P.; Rocha-Pereira, P.; Mota, A.; Figueiredo, A.; Teixeira, F. Chemopreventive Efficacy of Atorvastatin against Nitrosamine-Induced Rat Bladder Cancer: Antioxidant, Anti-Proliferative and Anti-Inflammatory Properties. Int. J. Mol. Sci. 2012, 13, 8482-8499.

AMA Style

Parada B, Reis F, Pinto Â, Sereno J, Xavier-Cunha M, Neto P, Rocha-Pereira P, Mota A, Figueiredo A, Teixeira F. Chemopreventive Efficacy of Atorvastatin against Nitrosamine-Induced Rat Bladder Cancer: Antioxidant, Anti-Proliferative and Anti-Inflammatory Properties. International Journal of Molecular Sciences. 2012; 13(7):8482-8499.

Chicago/Turabian Style

Parada, Belmiro; Reis, Flávio; Pinto, Ângela; Sereno, José; Xavier-Cunha, Maria; Neto, Paula; Rocha-Pereira, Petronila; Mota, Alfredo; Figueiredo, Arnaldo; Teixeira, Frederico. 2012. "Chemopreventive Efficacy of Atorvastatin against Nitrosamine-Induced Rat Bladder Cancer: Antioxidant, Anti-Proliferative and Anti-Inflammatory Properties." Int. J. Mol. Sci. 13, no. 7: 8482-8499.



Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert